Publication
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerCutaneous Melanomacivic_curation1.00
- drugMitogen-Activated Protein Kinase Kinase Inhibitorcivic_curation1.00
- drugSorafenibcivic_curation1.00
- drugTrametinibcivic_curation1.00
- geneBRAFcivic_curation1.00
- variantBRAF D594Acivic_curation1.00
- variantBRAF D594Vcivic_curation1.00
- variantBRAF K483Mcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 20141835
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF D594A1 | ||||||||
| Mitogen-Activated Protein Kinase Kinase Inhibitor + SorafenibSubstitutes | Cutaneous MelanomaALIAS | Predictive | E | Supports Sensitivity Response | 3 | accepted | EID1454Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF … (full text at CIViC) PMID 20141835 · Heidorn et al., 2010 · Open in CIViC | civic |
| BRAF D594V1 | ||||||||
| Sorafenib + TrametinibSubstitutes | Cutaneous MelanomaALIAS | Predictive | E | Supports Sensitivity Response | 3 | accepted | EID1456Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF … (full text at CIViC) PMID 20141835 · Heidorn et al., 2010 · Open in CIViC | civic |
| BRAF K483M1 | ||||||||
| Mitogen-Activated Protein Kinase Kinase Inhibitor + SorafenibSubstitutes | Cutaneous MelanomaALIAS | Predictive | E | Supports Sensitivity Response | 3 | accepted | EID1457Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF … (full text at CIViC) PMID 20141835 · Heidorn et al., 2010 · Open in CIViC | civic |